epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.
EPI-512, Phase III. Recruitment complete
Moderate to severe ulcerative colitis
WGB-512 induction against placebo in moderate to severe ulcerative colitis. Sponsor: Woodgrove Biologics (fictional), Immunology and GI.
QTLs at a glance
Data to September 30th 2026. Each measure links to its chart below.
Quality tolerance limits (acceptable ranges, in ICH E6(R3)), most important first. Priority is how likely this study's design makes a breach, times how strongly the evidence links the measure to a reliable result. Each has an early-warning line, a limit and a critical line where the study's power would fall to the escalation level.
Rank
QTL
Likelihood
Impact
Why it is likely here
Watched at sites by
Warning
Limit
Critical
1
Stopped study treatment earlyEvidence grade B
3
2
Placebo or no-added-treatment control arm (PD-05)From the design: What does the control arm receive? Placebo or no added treatment
Study drug at the siteTighter KRI threshold at sites in Turkey, for currency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026). The QTL itself stays study-wide.
12.5%
15%
22%
2
Ineligible patients randomisedEvidence grade B
2
2
Comorbidity exclusions (PD-15)From the design: Does the protocol exclude common comorbidities? Yes
Restrictive eligibility criteria and protocol complexity (EB-04)From the design: How many non-essential exclusions does the protocol carry? One or two
Eligibility criteria exclude patients (comorbidity, age, performance status, language) (PB-02)From the design: How many non-essential exclusions does the protocol carry? One or two; Does the protocol exclude common comorbidities? Yes
Restrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status) (PD-01)From the design: How many non-essential exclusions does the protocol carry? One or two
Number of eligibility criteria and complexity growth (PD-02)From the design: How many non-essential exclusions does the protocol carry? One or two
Missing primary endpoint data: running rate by month
Month
Patients
Rate
Sep 2022
1
0%
Dec 2022
11
0%
Mar 2023
29
0%
Jun 2023
51
3.9%
Sep 2023
79
7.6%
Dec 2023
114
12.3%
Mar 2024
138
10.1%
Jun 2024
165
9.1%
Sep 2024
190
8.4%
Dec 2024
217
8.8%
Mar 2025
259
8.9%
Jun 2025
289
8.7%
Sep 2025
313
8.3%
Dec 2025
348
7.8%
Mar 2026
377
7.4%
Jun 2026
412
7.8%
The acceptable range is the drop-out the study's power calculation allowed for (planner parameters, D24); the early-warning line sits at two-thirds of it
Lost to follow-up or withdrew consent
Within range% of patients; benchmark median 3.7%
Show data
Lost to follow-up or withdrew consent: running rate by month
Month
Patients
Rate
Mar 2022
1
0%
Jun 2022
11
0%
Sep 2022
29
0%
Dec 2022
51
0%
Mar 2023
79
0%
Jun 2023
116
0.9%
Sep 2023
140
1.4%
Dec 2023
167
1.8%
Mar 2024
192
1.6%
Jun 2024
219
1.8%
Sep 2024
261
1.9%
Dec 2024
292
2.1%
Mar 2025
316
2.2%
Jun 2025
351
2%
Sep 2025
380
2.6%
Dec 2025
415
2.7%
Mar 2026
448
2.9%
Jun 2026
471
3.2%
epiClinical assumption: above the combined benchmark median of 3.7% and in line with published case studies that set limits around 4% for unknown survival status
Patients needed before a QTL is judged: 50. epiClinical assumption: QTL rates are unstable with few patients, and many early breaches in vendor data were noise (review note 01).
Breaches and decisions
Near miss
Missing primary endpoint data
Early warning October 2023
Status
Watched; closed without action
What the evaluation found
A run of missed six-month visits at two sites, during a change of study nurse, pushed missing endpoint data over the early-warning line. Both sites rebooked the visits they could, and the rate fell back below the line within six months.
Why it matters
None lasting: the rate stayed well inside the acceptable range.
A fictional scenario written to show a warning that needed watching but not action.
Critical lines assume each study was designed for 80% power at a two-sided 5% level, and mark where power would fall to 70%. Missing outcome data can bias a result well before it costs power, so its limit, not its critical line, is the one to act on.